Apellis is cutting about 40 non-U.S. employees, as it prioritizes commercializing geographic atrophy treatment Syfovre in the U.S.
https://www.globenewswire.com/news-release/2025/01/13/3008580/0/en/Apellis-Highlights-Commercial-Growth-and-Strategic-Priorities-at-43rd-Annual-J-P-Morgan-Healthcare-Conference.html